Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

GH and Cardiovascular Risk Factors

This study has been completed.
Information provided by (Responsible Party):
Prof. dr. M.L. Drent, VU University Medical Center Identifier:
First received: June 11, 2013
Last updated: May 6, 2014
Last verified: May 2014

Rationale: Abnormally low and high levels of insulin-like growth factor-I (IGF-I) are both associated with increased metabolic risk. Since (U-shaped) associations of IGF-I, within the normal range, have also been found with cardiovascular risk factors and disease in the general population, it would be interesting to investigate if this association can also be found in growth hormone deficient (GHD) adults treated with Growth Hormone (GH). This could be of interest for endocrinologists prescribing GH in clinical practice because strict dosing may become even more important. Next to that, scientific evidence for clinical practice is wanted.

Objective: Next to cardiovascular risk factors (main objectives: body composition and lipid profile; secondary objectives: remainder) we investigate the effect on glucose metabolism, physical performance, and neuropsychological functioning of different levels of IGF-I in GH treated GHD men and women.

Study design: Open-label randomized trial.

Study population: At least 32 subjects, both childhood as adult onset GHD men and women, receiving GH treatment for at least one year, with an age between 20 and 65 years.

Intervention: At entry subjects are already receiving GH treatment according to general clinical practice, and are expected to demonstrate an IGF-I concentration of 0 - 1 SD score (SDS) (normal dose). The group of men and group of women will be randomized to receive either a decrease of their regular dose of GH treatment (IGF-I target level of -2 - -1 SDS) (low dose), or an increase of their regular dose, (IGF-I target level of 1 - 2 SDS) (high dose) for at least 24 weeks.

Condition Intervention Phase
Growth Hormone Deficiency
Cardiovascular Diseases
Metabolic Syndrome
Physical Activity
Drug: Change in daily dosage of Growth Hormone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I Concentration

Resource links provided by NLM:

Further study details as provided by VU University Medical Center:

Primary Outcome Measures:
  • Change in cardiovascular risk (body composition and lipid profile) [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Change in cardiovascular risk (inflammatory markers, vascular stiffness, endothelial function, presence of the metabolic syndrome) [ Time Frame: 24 weeks ]
  • Change in physical performance (muscle strength, physical activity) [ Time Frame: 24 weeks ]
  • Change in glucose metabolism (fasting and 2hr postprandial glucose, insulin resistance) [ Time Frame: 24 weeks ]
  • Change in neuropsychological functioning (QoL, cognition, mood) [ Time Frame: 24 weeks ]

Enrollment: 32
Study Start Date: May 2013
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Low dose Growth Hormone
Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
Drug: Change in daily dosage of Growth Hormone
Other Name: Change in daily dosage of Somatropin
Active Comparator: High dose Growth Hormone
Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
Drug: Change in daily dosage of Growth Hormone
Other Name: Change in daily dosage of Somatropin


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ongoing surveillance at our centre (VUmc)
  • Stable substitution therapy for other pituitary hormone deficiencies

Exclusion Criteria:

  • Subjects with a craniopharyngioma as cause of their GHD or pituitary deficiencies
  • Contraindications for the use of GH treatment
  • (Receiving treatment for) malignant disease (in the past)
  • Cardiovascular event less than one year prior to inclusion
  • Participation in other studies
  • Subjects, who in the opinion of the investigator, are unsuitable in any other way to participate in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01877512

VU University Medical Center
Amsterdam, PO Box 7057, Netherlands, 1007 MB
Sponsors and Collaborators
VU University Medical Center
Principal Investigator: Madeleine L. Drent, MD PhD VU University Medical Center
  More Information

Responsible Party: Prof. dr. M.L. Drent, MD PhD, VU University Medical Center Identifier: NCT01877512     History of Changes
Other Study ID Numbers: 2013/12
U1111-1142-9659 ( Other Identifier: Universal Trial Number )
2012-005066-36 ( EudraCT Number )
Study First Received: June 11, 2013
Last Updated: May 6, 2014

Additional relevant MeSH terms:
Cardiovascular Diseases
Metabolic Syndrome X
Endocrine System Diseases
Dwarfism, Pituitary
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 22, 2017